Sanofi, Global Genomics Group Partner
News Jan 06, 2016
Under the terms of the agreement, Sanofi and G3 will utilize G3's proprietary platform with data from its G3LOBAL DatabaseTM to further unravel the molecular underpinnings of LDL-cholesterol regulation and to better understand which patients may benefit from interference with such novel signaling pathways.
"Our G3LOBAL DatabaseTM has been developed as a tool that enables drug developers and biomedical research scientists to better understand molecular networks that underlie human disease and thus improve the drug discovery and development process," said Szilard Voros, M.D., founder and chief executive officer of G3. "We believe that precision phenotyping, pan-omics and systems-biology driven bioinformatics are the key components of target identification, validation and the elucidation of novel pathways."
G3 will receive undisclosed payments from Sanofi for the collaboration.
scNMT-seq Allows Analysis of Connections Between Nucleosomes, Methylation and TranscriptionNews
A new bioinformatics technique allows researchers to study three key processes inside the cell simultaneously.READ MORE
Targeted Drug Could be Used to Treat Advanced Cancers Located Anywhere in the BodyNews
A new targeted drug could be used to treat a small number of advanced cancers no matter where they grow in the body.READ MORE
I See What You're Thinking: Successful Image Reconstruction Using EEGNews
In a world first, scientists have been able to recreate images perceived by test subjects using only data from their EEG scans.READ MORE